Skip to main content

Table 1 Methodology

From: Effectiveness of second generation antipsychotics: A systematic review of randomized trials

Study Comparators Doses (DDD) Diagnoses Age Phase/status N0/Nitt/N1 Follow-up Funding
FIRST EPISODE         
Crespo-Facorro et al. [24] Haloperidol
Olanzapine
Risperidone
5.4 mg (0.68)
15.3 mg (1.53)
4.0 mg (0.80)
Schizophrenia and related, non-affective psychosis 15–60 years Acute, first episode in- and outpatients 172/172/165 6 weeks Independent
McEvoy et al. [25] Olanzapine
Quetiapine
Risperidone
11.7 mg (1.17)
506.0 mg (1.27)
2.4 mg (0.5)
Schizophrenia, schizoaffective- schizophreniform disorder 16–40 years Acute, first episode in- and outpatients 400/-/119 12 months AstraZeneca company
Robinson et al. [26] Olanzapine
Risperidone
11.8 mg (1.18)
3.9 mg (0.78)
Schizophrenia, schizoaffective- schizophreniform disorder 16–40 years Acute, first episode 120/112/81 4 months Independent
ACUTE PHASE         
Chrzanowski et al. [27] Aripiprazole
Olanzapine
22.0 mg (1.47)
14.2 mg (1.42)
Schizophrenia ≥ 18 years Acute psychosis/chronic stable in- and outpatients 214/214/147 52 weeks BMS/Otsuka
Kraus et al. [28] Olanzapine
Risperidone
12.4 mg (1.24)
3.4 mg (0.39)
Psychosis; positive symptoms 18–60 years Acute, inpatients 85/-/68 Not defined Independent
McCue et al. [29] Aripiprazole
Haloperidol
Olanzapine Quetiapine Risperidone Ziprasidone
21.8 mg1 (1.45)
16.0 mg 1(2.00)
19.1 mg 1(1.91)
652.5 mg1 (1.63)
5.2 mg1 (1.04)
151.2 mg1 (1.89)
Schizophrenia, schizoaffective- schizophreniform disorder ≥ 18 years Acute, inpatients 327/319/301 3 weeks Independent
CHRONIC PHASE         
Jerrel [30] Olanzapine
Risperidone
Haloperidol
Haloperidol (d)
Fluphenazine (d)
13.8 mg (1.38)
5.3 mg (1.06)
15.5 mg (1.93)
6.3 mg (1.92)
3.0 mg (0.43)
Schizophrenia and schizoaffective disorder 18–54 years Chronic, inpatients acute care 108/-/84 12 months Independent
Lieberman et al. [31] Olanzapine
Perphenazine
Quetiapine
Risperidone
Ziprasidone
20.1 mg (2.01)
20.8 mg (0.69)
543.4 mg (1.36)
3.9 mg (0.78)
112.8 mg (1.41)
Schizophrenia 18–65 years Chronic, not treatment resistant, in- and outpatients 1493/1432/371 18 months Independent
Mullen et al. [32] Quetiapine
Risperidone
329.0 mg (0.82)
5.0 mg (1.00)
Psychotic disorders2 > 18 years Outpatients 728/-/493 4 months AstraZeneca company
Ritchie et al. [33] Olanzapine
Risperidone
9.9 mg (0.99)
1.7 mg (0.34)
Schizophrenia > 60 years Outpatients, switch from FGAs 66/61/52 switch period (mean 40 days) Eli Lilly company
Ritchie et al. [34] Olanzapine
Risperidone
12.4 mg (1.24)
2.0 mg (0.39)
Schizophrenia > 60 years Outpatients, switch from FGAs 66/61/42 6 months Eli Lilly company
Rosenheck et al. [35] Olanzapine
Perphenazine
Quetiapine
Risperidone
Ziprasidone
Not disclosed
-
-
-
-
Schizophrenia 18–65 years Chronic, not treatment resistant, in- and outpatients 1493/1424/363 18 months Independent
Stroup et al. [36] Olanzapine
Quetiapine
Risperidone
Ziprasidone
20.5 mg (2.05)
565.2 mg (1.41)
4.1 mg (0.82)
115.9 mg (1.45)
Schizophrenia 18–65 years Chronic, not treatment resistant, in- and outpatients, discontinued previous SGA because of intolerability 444/333/88 18 months Independent
Stroup et al. [37] Olanzapine
Quetiapine
Risperidone
20.7 mg (2.07)
586.1 mg (1.47)
3.7 mg (0.74)
Schizophrenia 18–65 years Chronic, not treatment resistant, in- and outpatients, discontinued Perphenazine 115/114/37 18 months Independent
Swartz et al. [38] Olanzapine
Perphenazine
Quetiapine
Risperidone
Ziprasidone
Not disclosed
-
-
-
-
Schizophrenia 18–65 years Chronic, not treatment resistant, in- and outpatients 1493/985/455 18 months Independent
Tunis et al. [39] Olanzapine
Risperidone
Haloperidol
Perphenazine
13.5 mg (1.35)
4.9 mg (0.99)
11.0 mg (1.37)
14.2 mg (0.47)
Schizophrenia, schizoaffective- schizophreniform disorder, ≥ 18 on the BPRS ≥ 18 years Primarily outpatients 664/-/455 12 months Eli Lilly company
  1. Abbreviations: Comparators = Antipsychotics being compared in the studies; Doses = Mean daily doses of the antipsychotics; DDD = Defined Daily Doses of the antipsychotics; Diagnoses = Diagnoses defined in inclusion criteria; Age = Age of study participants; Phase = Phase of psychotic illness of study participants: acute or chronic; Status = Status of study participants: first episode, inpatients, outpatients; N0 = Number of participants at baseline; Nitt = Number in intention to treat group (not disclosed in all studies as indicated by (-)), N1 = Number of completers; Follow-up = Duration of study follow-up; Funding = Financial support of study; BMS = Bristol-Myers Squibb; Otsuka = Otsuka America Pharmaceuticals, inc.; Independent = Study financially supported by sources independent of the pharmaceutical industry. A = Aripiprazole, FGAs = First generation antipsychotics, H = Haloperidol, O = Olanzapine, P = Perphenazine, Q = Quetiapine, R = Risperidone, Z = Ziprasidone, BPRS = the Brief Psychiatric Rating Scale, d = depot formulation.
  2. 1 Mean maximum daily dosage
  3. 2 Schizophrenia, schizophreniform -, schizoaffective -, delusional disorder, major depressive disorder with psychotic features, Alzheimer's dementia with psychotic symptoms, vascular dementia, dementia due to substance abuse